Third Harmonic Bio (THRD) | Financial Analysis & Statements
Third Harmonic Bio, Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
0
Operating Income
-18.7M
Net Income
-15.8M
EPS (Diluted)
$-0.35
Balance Sheet Metrics
Total Assets
279.8M
Total Liabilities
7.2M
Shareholders Equity
272.6M
Debt to Equity
0.03
Cash Flow Metrics
Operating Cash Flow
-11.8M
Free Cash Flow
-13.5M
Revenue & Profitability Trend
Third Harmonic Bio Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 36.5M | 24.0M | 24.4M | 15.7M | 10.0M |
| Selling, General & Administrative | 22.4M | 20.0M | 13.3M | 3.3M | 1.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 58.9M | 44.0M | 37.7M | 19.0M | 11.1M |
| Operating Income | -58.9M | -44.0M | -37.7M | -19.0M | -11.1M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 13.4M | 13.1M | 2.6M | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | -6.0K | 22.0K | -2.0K | -10.6M | -1.7M |
| Pre-tax Income | -45.5M | -30.8M | -35.2M | -29.6M | -12.8M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -45.5M | -30.8M | -35.2M | -29.6M | -12.8M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -58.8M | -43.9M | -37.7M | -19.0M | -11.1M |
| EPS (Basic) | - | $-0.78 | $-2.45 | $-0.80 | $-0.35 |
| EPS (Diluted) | - | $-0.78 | $-2.45 | $-0.80 | $-0.35 |
| Basic Shares Outstanding | - | 39645392 | 14353102 | 26288583 | 26288583 |
| Diluted Shares Outstanding | - | 39645392 | 14353102 | 26288583 | 26288583 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Third Harmonic Bio Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 285.1M | 269.1M | 288.9M | 128.3M | 8.3M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 5.5M | 3.4M | 4.0M | 884.0K | 156.0K |
| Total Current Assets | 290.5M | 272.4M | 292.8M | 129.2M | 8.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 3.8M | 4.3M | - | - |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 901.0K | 1.3M | 1.5M | - | - |
| Total Non-Current Assets | 4.1M | 5.3M | 5.8M | 0 | 0 |
| Total Assets | 294.6M | 277.7M | 298.7M | 129.2M | 8.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.9M | 1.8M | 2.1M | 1.8M | 581.0K |
| Short-term Debt | 859.0K | 745.0K | 385.0K | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 59.0K | - | 233.0K | 2.0K | - |
| Total Current Liabilities | 7.1M | 5.4M | 5.7M | 5.7M | 2.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.3M | 3.2M | 4.0M | 0 | - |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | 883.0K |
| Total Non-Current Liabilities | 2.3M | 3.2M | 4.0M | 170.2M | 24.6M |
| Total Liabilities | 9.5M | 8.6M | 9.6M | 175.9M | 26.8M |
| Equity | |||||
| Common Stock | 5.0K | 4.0K | 4.0K | 1.0K | 1.0K |
| Retained Earnings | -159.7M | -114.2M | -83.4M | -48.2M | -18.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 285.2M | 269.1M | 289.1M | -46.7M | -18.4M |
| Key Metrics | |||||
| Total Debt | 3.2M | 4.0M | 4.3M | 0 | 0 |
| Working Capital | 283.4M | 267.0M | 287.2M | 123.5M | 6.2M |
Balance Sheet Composition
Third Harmonic Bio Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -45.5M | -30.8M | -35.2M | -29.6M | -12.8M |
| Depreciation & Amortization | 49.0K | 35.0K | 1.0K | - | - |
| Stock-Based Compensation | 11.1M | 9.6M | 4.8M | 510.0K | 195.0K |
| Working Capital Changes | -272.0K | -13.0K | -772.0K | 1.2M | 324.0K |
| Operating Cash Flow | -33.9M | -20.7M | -31.1M | -17.3M | -10.6M |
| Investing Activities | |||||
| Capital Expenditures | -10.0K | -169.0K | -36.0K | - | - |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -10.0K | -169.0K | -36.0K | - | - |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 48.7M | -465.0K | 195.9M | 135.7M | 10.8M |
| Free Cash Flow | -34.5M | -20.6M | -35.0M | -15.7M | -9.2M |
| Net Change in Cash | 14.8M | -21.3M | 164.7M | 118.5M | 225.0K |
Cash Flow Trend
Third Harmonic Bio Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
12.46
Forward P/E
-3.49
Price to Book
0.89
PEG Ratio
0.17
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-19.94%
Return on Assets
-14.60%
Financial Health
Current Ratio
54.10
Debt to Equity
1.10
Beta
2.13
Per Share Data
EPS (TTM)
$-1.24
Book Value per Share
$6.06
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| THRD | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Editas Medicine | 323.0M | - | 11.83 | -198.14% | 0.00% | 66.34 |
| Silence Therapeutics | 370.3M | -4.16 | 6.04 | -90.27% | 61.54% | 0.26 |
| Alector | 266.0M | -1.73 | 8.74 | -181.56% | 0.00% | 118.22 |
Financial data is updated regularly. All figures are in the company's reporting currency.
